We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody therapeutics for autoimmune and inflammatory indications, announced the completion of a $70 million Series A financing from premier investors Fidelity Management & Research ...
Horizon Pharma says it has completed enrollment in a confirmatory Phase III trial of teprotumumab in patients living with moderate-to-severe active thyroid...